Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer

NCT00281996 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

19

Enrollment

OTHER

Sponsor class

Stopped Closed to accrual to allow enrollment on another more promising trial.

Conditions

Pancreatic Cancer

Interventions

DRUG: Gemcitabine
DRUG: Imatinib mesylate

Sponsor

Northwestern University

Collaborators

[object Object]